We look at scientific innovation from different angles, seeking better solutions for the unmet needs of patients.
KalVista Pharmaceuticals is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with our first product for hereditary angioedema (HAE), a rare genetic disease with unpredictable attacks of tissue swelling that can be life threatening.
For more than a decade, KalVista has been dedicated to advancing science to address the unmet needs of the HAE community. Today, our team of more than 250 employees worldwide is deeply motivated to develop medicines that meaningfully improve the lives of people with HAE.
Our debut rare disease therapy was approved by the FDA as the first and only oral on-demand treatment for HAE and has the potential to transform HAE treatment worldwide.
As an oral medication, it is designed to offer an alternative to the complexities and treatment burden of other approved HAE treatment options, which require injectable administration or chronic dosing.
Our pipeline innovations include preclinical programs for oral Factor XIIa inhibitors, expanding our HAE product portfolio to include prophylactic treatment of HAE, as well as pushing ahead with new treatments for other diseases, such as thrombosis and inflammation.
YOU ARE NOW LEAVING KALVISTA.COM
You are now being directed to another KalVista website that contains information about specific treatment(s)